SWP
TCRX icon

Strategic Wealth Partners’s TScan Therapeutics TCRX Stock Holding History

Strategic Wealth Partners’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$314 Hold
311
– – ﹤0.01% 1351
2025
Q4 		$311 Hold
311
– – ﹤0.01% 1367
2025
Q3 		$566 Hold
311
– – ﹤0.01% 1250
2025
Q2 		$451 Buy
+311
New +$449 ﹤0.01% 1084

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Strategic Wealth Partners's TCRX Position: Q1 2026 in Review

Strategic Wealth Partners held its TScan Therapeutics (TCRX) position steady in Q1 2026 at 311 shares worth $314. The position accounts for ﹤0.01% of the portfolio, ranked #1351.

Strategic Wealth Partners first reported a position in TCRX in Q2 2025 and has held it in 4 quarters since. The position peaked at $566 in Q3 2025. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • Strategic Wealth Partners held 311 shares of TScan Therapeutics worth $314 as of Q1 2026.
  • Strategic Wealth Partners left its TScan Therapeutics share count unchanged in Q1 2026.
  • TScan Therapeutics made up ﹤0.01% of Strategic Wealth Partners's portfolio in Q1 2026, its #1351 holding.
  • Strategic Wealth Partners first reported a position in TScan Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Strategic Wealth Partners's TScan Therapeutics position peaked at $566 in Q3 2025.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Strategic Wealth Partners's 13F filing for Q1 2026, filed 12 May 2026.